Zygomycetes in human disease.

By J. Ribes, Carolyn L. Vanover-Sams, D. J. Baker. Clinical Microbiology Reviews, 2000

1,388 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Small Animals

View Paper: https://www.semanticscholar.org/paper/8053c04dbdf2aa1b3e5f66bdbacb49b8d52da044

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. D. Kontoyiannis
2. T. Walsh
3. J. Guinea
4. A. Ibrahim
5. B. Spellberg
6. M. Arendrup
7. M. Pfaller
8. D. Diekema

In Infectious Diseases

1. D. Kontoyiannis
2. Georgios Chamilos
3. J. Guinea
4. M. Arendrup
5. M. Pfaller
6. D. Diekema

In Small Animals

1. J. Guinea
2. D. Kontoyiannis

Citations in the corpus

• Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management (2005, background): “Among the Mucoraceae, Rhizopus oryzae (Rhizopus arrhizus) is by far the most common cause of infection (129).”
• Epidemiology and outcome of zygomycosis: a review of 929 reported cases. (2005, neutral): “Sex Male 605/929 (65) 330/605 (55) Female 324/929 (35) 174/324 (54) No underlying condition at time of infection, cause of infection Overall 176/929 (19) 61/176 (35) Penetrating trauma 44/176 (25) 10/44 (23) Surgery 32/176 (18) 12/32 (38) Burns 11/176 (6) 7/11 (64) Other 89/176 (51) 32/89 (36) Under”
• Epidemiology and clinical manifestations of mucormycosis. (2012, background): “In premature neonates, gastrointestinal mucormycosis presents as necrotizing enterocolitis, whereas in neutropenic patients, it does so as a masslike appendiceal or ileal lesion [3, 157].”
• Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. (2008, background): “ing monocytopenia, are major risk factors for zygomycosis [1].”
• Global Epidemiology of Mucormycosis (2019, background): “Humans acquire the infection predominantly by inhalation of sporangiospores, occasionally by ingestion of contaminated food or traumatic inoculation [1,2].”
• Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. (2006, background): “Therefore, there is an unmet clinical need for an orally administered agent with activity against Zygomycetes.”
• Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. (2002, result): “The results of the present study emphasize the importance of severe neutropenia in the pathogenesis of disease caused by Scedosporium species, whereas GVHD and its therapy (corticosteroids) have a stronger association with Zygomycetes infection [25].”
• ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. (2014, background): “Grinding of specimens should therefore be avoided [32].”
• Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. (2005, background): “Trends in the reporting of zygomycosis infections can be further complicated by the fact that nosocomial transmission of zygomycosis, including outbreaks, have been rarely reported [14].”
• Histopathologic Diagnosis of Fungal Infections in the 21st Century (2011, background): “Mucorales genera produce nonpigmented, wide (5- to 20- m), thin-walled, ribbon-like hyphae with few septations (pauciseptate) and right-angle branching (132).”
• Pathogenesis of mucormycosis. (2012, background): “Rhizopus oryzae is the most common organism isolated from patients with mucormycosis and is responsible for 70% of all cases of mucormycosis [2–4].”